Mamale Kalpana, Shukla Shalini, Mahale Priyanka, Mhaske Akshada, Kaundal Ravinder K, Shukla Rahul
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Raebareli (NIPER-R), Transit Campus, Bijnor-Sisendi Road, Sarojini Nagar, Near CRPF Base Camp, Lucknow, UP, 226002, India.
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Raebareli (NIPER-R), Transit Campus, Bijnor-Sisendi Road, Sarojini Nagar, Near CRPF Base Camp, Lucknow, UP, Lucknow, 226002, India.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun;398(6):7489-7504. doi: 10.1007/s00210-024-03741-0. Epub 2025 Jan 4.
Atopic dermatitis (AD) is a chronic skin inflammatory ailment commonly observed in young children and adults. Various therapeutic modalities are already explored for mitigation of AD but for prolong application very few modalities are recommended. Considering these challenges, we have successfully developed gliclazide-loaded hydrogels using the physical dispersion method. For preclinical assessment, we developed a DNCB induced an AD-like phenotype in mice, characterized by increased dermatitis index, scratching interval, ear thickness and weight, spleen and lymph node enlargement, mast cell infiltration, and elevated oxidative stress. However, topical application of the GLZ hydrogel significantly improved these DNCB-induced symptoms. Mice treated with the GLZ hydrogel exhibited a marked reduction in inflammatory markers in histological evaluations. Specifically, there was a decrease in epidermal thickness and mast cell infiltration compared to the DNCB + Vehicle group. Additionally, the topical GLZ hydrogel attenuated the AD-like phenotype by reducing oxidative stress markers. Importantly, these therapeutic effects occurred without significantly affecting blood glucose levels, highlighting the safety of the topical GLZ hydrogel. These findings demonstrate the potential of GLZ-loaded hydrogels as an effective and safe topical treatment for alleviating the symptoms of AD by targeting oxidative stress and inflammation.
特应性皮炎（AD）是一种常见于幼儿和成人的慢性皮肤炎症性疾病。已经探索了各种治疗方法来缓解AD，但对于长期应用，推荐的方法很少。考虑到这些挑战，我们已通过物理分散法成功开发了载有格列齐特的水凝胶。为了进行临床前评估，我们在小鼠中诱导出了一种类似AD的表型，其特征为皮炎指数增加、搔抓间隔时间缩短、耳部厚度和重量增加、脾脏和淋巴结肿大、肥大细胞浸润以及氧化应激升高。然而，局部应用格列齐特水凝胶显著改善了这些由二硝基氯苯（DNCB）诱导的症状。在组织学评估中，用格列齐特水凝胶治疗的小鼠炎症标志物显著减少。具体而言，与DNCB+赋形剂组相比，表皮厚度和肥大细胞浸润减少。此外，局部应用格列齐特水凝胶通过降低氧化应激标志物减轻了类似AD的表型。重要的是，这些治疗效果在不显著影响血糖水平的情况下出现，突出了局部应用格列齐特水凝胶的安全性。这些发现表明，载有格列齐特的水凝胶作为一种有效且安全的局部治疗方法，通过针对氧化应激和炎症来缓解AD症状具有潜力。
